Trial · NCT02329964

Effectiveness of Sugammadex in LMS Surgery

NCT02329964, Phase 4, Unknown, Korea University Anam Hospital; results first posted 2015-09-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effectiveness of Sugammadex in LMS Surgery. Trials, record NCT02329964. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02329964

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effectiveness of Sugammadex in LMS Surgery
NCT number: NCT02329964
Status: Unknown
Phases: Phase 4
Enrollment: 80 participants, actual
Lead sponsor: Korea University Anam Hospital
Conditions: Muscle Relaxation
Interventions: Sugammadex, Neostigmine
First posted: 2015-01-01
Last updated: 2015-09-28
Results first posted: 2015-09-28
Limitations and caveats: The surgical rating score was assessed on the basis of the degree of laryngx exposure. This was influenced not only by neuromuscular relaxation but also by anatomical factors.

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Recovery of T1 to 90%	from the end of surgery(when the surgeon removes the suspension laryngoscope ) to time when the TOF ratio is 0.9, up to 30 minutes	we measure the time from the end of surgery to recovery of the TOF 0.9. The end of surgery is defined as the time when the direct laryngoscope, aided by an operation microscope, is removed.
Primary	Surgical Rating Score	during surgery	describe by surgeon under his subjective opinion. 1 - extremely poor conditions 2- poor conditions 3- acceptable conditions 4- good conditions 5- optimal conditions
Primary	Addition of Neuromuscular Blocking Agents	during surgery	Repeated small boluses or drip of Succinylcholine, or small boluses of nondepolarizing muscle relaxants with intermediate duration are usually followed. In this protocol, cisatracurium was injected after intubation to maintain neuromuscular blockade during surgery. We measure the requirement of additive dose of neuromuscular blocker to ensure that neuromuscular blockade remains below T2 during surgery
Primary	Recovery of T1 to 10%	from the end of surgery to time when the TOF ratio is 0.1, up to 30 minutes	we measure the time from the end of surgery to recovery of the TOF 0.1. The end of surgery is defined as the time when the direct laryngoscope, aided by an operation microscope, is removed.
Secondary	Time to Extubation	from the end of surgery to extubate a tracheal tube	We expected the emergence time is shorter in R-S group than S-C-N group. So we measure the time from the end of surgery to recovery of the TOF 0.9, and the time from the end of surgery to extubation
Secondary	Time to First Spontaneous Breath	from end of surgery to first spontaneous breaths	time from end of surgery to first spontaneous breaths
Secondary	Time to Eye Opening	from end of surgery to opening of the eyes to verbal commands	We expected the emergence time is shorter in R-S group than S-C-N group. So we measure the time from the end of surgery to opening of the eyes to verbal commands.
Other	Length of Stay in te Operating Room	time from in to out of the operating room	LMS surgery has short operation time and ambulatory setting. So the length of stay in the operating room will have significant. We expected the lengh of stay in the operating room is more shorter in R-S group than S-C-N group.
Other	Anesthesia Time	from the anesthesia start to end	time from propofol injection to extubation

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Recovery of T1 to 90%	from the end of surgery(when the surgeon removes the suspension laryngoscope ) to time when the TOF ratio is 0.9, up to 30 minutes	seconds	MEDIAN
PRIMARY	Surgical Rating Score	during surgery	score	MEDIAN
PRIMARY	Addition of Neuromuscular Blocking Agents	during surgery	participants	NUMBER
SECONDARY	Time to Extubation	from the end of surgery to extubate a tracheal tube	seconds	MEDIAN
OTHER_PRE_SPECIFIED	Length of Stay in te Operating Room	time from in to out of the operating room	minutes	MEAN
OTHER_PRE_SPECIFIED	Anesthesia Time	from the anesthesia start to end	minutes	MEAN
PRIMARY	Recovery of T1 to 10%	from the end of surgery to time when the TOF ratio is 0.1, up to 30 minutes	seconds	MEDIAN
SECONDARY	Time to First Spontaneous Breath	from end of surgery to first spontaneous breaths	seconds	MEDIAN
SECONDARY	Time to Eye Opening	from end of surgery to opening of the eyes to verbal commands	seconds	MEDIAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Recovery of T1 to 90%	R-S Group	377	Inter-Quartile Range 334 to 435	seconds
Recovery of T1 to 90%	S-C-N Group	240	Inter-Quartile Range 180 to 360	seconds
Surgical Rating Score	R-S Group	5.0	Inter-Quartile Range 5.0 to 5.0	score
Surgical Rating Score	S-C-N Group	5.0	Inter-Quartile Range 4.0 to 5.0	score
Addition of Neuromuscular Blocking Agents	R-S Group	0		participants
Addition of Neuromuscular Blocking Agents	S-C-N Group	20		participants
Time to Extubation	R-S Group	430	Inter-Quartile Range 366 to 510	seconds
Time to Extubation	S-C-N Group	380	Inter-Quartile Range 286 to 495	seconds
Length of Stay in te Operating Room	R-S Group	31.0	Standard Deviation 7.7	minutes
Length of Stay in te Operating Room	S-C-N Group	38.6	Standard Deviation 7.5	minutes

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	R-S Group	40
Overall Study	STARTED	S-C-N Group	40
Overall Study	COMPLETED	R-S Group	40
Overall Study	COMPLETED	S-C-N Group	40
Overall Study	NOT COMPLETED	R-S Group	0
Overall Study	NOT COMPLETED	S-C-N Group	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	R-S Group
Total, all-cause mortality	S-C-N Group
Total, other adverse events	R-S Group	0	40
Total, other adverse events	S-C-N Group	0	40
Total, serious adverse events	R-S Group	0	40
Total, serious adverse events	S-C-N Group	0	40

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19387176	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
R-S Group vs S-C-N Group: Addition of Neuromuscular Blocking Agents	Trial comparisons
R-S Group vs S-C-N Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02329964

GET https://conductscience.org/api/trials/v1/NCT02329964/registered

API reference For AI assistants